In a study published in Nature Communications, researchers at the Beijing Institute of Stem Cells and Regeneration (BISCRM) ...

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 ...

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION).

G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...

Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body ...

Impressions Face + Body owner says he's noticed a spike in interest from clients hoping to get face and body-lifts offered ...

It was the first in a series of drugs that are, for the first time, effective against obesity and can help lessen the moral ...

Vikrant Shrotriya, Corporate Vice President & Managing Director of Novo Nordisk India, during a session on India Today Conclave 2025, said that many celebrities may not want to admit to taking Ozempic ...

Despite acknowledging that older adults are a high-risk population for suicide, the websites of suicide prevention ...